GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » Book Value per Share

Iterum Therapeutics (Iterum Therapeutics) Book Value per Share : $-0.37 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Iterum Therapeutics Book Value per Share?

Iterum Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $-0.37.

During the past 12 months, Iterum Therapeutics's average Book Value Per Share Growth Rate was -125.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 68.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Iterum Therapeutics was 68.60% per year. The lowest was -62.00% per year. And the median was 3.30% per year.

Iterum Therapeutics's current price is $1.35. Its book value per share for the quarter that ended in Mar. 2024 was $-0.37. Hence, today's PB Ratio of Iterum Therapeutics is .

During the past 8 years, the highest P/B Ratio of Iterum Therapeutics was 4.08. The lowest was 0.79. And the median was 1.30.


Iterum Therapeutics Book Value per Share Historical Data

The historical data trend for Iterum Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iterum Therapeutics Book Value per Share Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial -26.47 -15.34 4.12 2.22 -0.47

Iterum Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 0.55 0.26 -0.47 -0.37

Competitive Comparison of Iterum Therapeutics's Book Value per Share

For the Biotechnology subindustry, Iterum Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iterum Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's PB Ratio falls into.



Iterum Therapeutics Book Value per Share Calculation

Iterum Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.40-0.00)/13.50
=-0.47

Iterum Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.15-0.00)/16.47
=-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Iterum Therapeutics  (NAS:ITRM) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Iterum Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Iterum Therapeutics (Iterum Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Fitzwilliam Court, 1st Floor, Leeson Close, Dublin, IRL, 2
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
Executives
Michael W. Dunne officer: Chief Scientific Officer DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Fishman Corey N. director, officer: President & CEO DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Sailaja Puttagunta officer: Chief Medical Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Brenton Karl Ahrens director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Judith M. Matthews officer: Chief Financial Officer 200 WEST MONROE ST., SUITE 1575, CHICAGO IL 60606
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Hawkeye Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Catapult Fund Llc 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Master Fund Ii Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Offshore Master Fund Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Iterum Therapeutics (Iterum Therapeutics) Headlines